Compare AbbVie Inc (ABBV) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? AbbVie Inc trades at $249.52 (market cap $438.19B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.93. The key difference: AbbVie Inc pays a 2.79% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | RDTE | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $34.20 |
52-Week Low | $197.38 | $26.40 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 1.59% with bullish technical signals and strong analyst support. The company demonstrates solid revenue growth to $61.16B in 2025, though net margins have compressed to 6.9%. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.65 surpassing estimates. Technical indicators show bullish momentum with the current price near resistance at $249, while RSI suggests potential oversold conditions at lower timeframes.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 price target offering 12.6% upside. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s and regulatory risks require monitoring. The company's dividend growth streak and robust pipeline support long-term value, but investors should weigh execution risks against current valuation multiples.
RDTE trades at $28.91, up 1.19% today, but technical indicators signal a bearish trend with moving averages showing significant sell pressure. The stock exhibits a consistent dividend distribution pattern, with multiple payments scheduled through mid-2026. Recent news coverage highlights the ETF's high-yield strategy but raises concerns about structural risks and capital erosion potential.
The outlook remains cautious due to the bearish technical structure and fundamental concerns about the covered-call strategy's sustainability. Investment opportunity exists for income-focused investors attracted to the dividend yield, but risks include capped upside participation and potential NAV deterioration during market rallies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
